Adage Capital Partners GP L.L.C. Sells 5,135,190 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Adage Capital Partners GP L.L.C. trimmed its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 46.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,994,810 shares of the company's stock after selling 5,135,190 shares during the period. Adage Capital Partners GP L.L.C. owned 4.36% of Compass Therapeutics worth $8,692,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after acquiring an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics during the 4th quarter valued at $26,000. Mariner LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at $30,000. Sequoia Financial Advisors LLC purchased a new position in shares of Compass Therapeutics during the fourth quarter valued at $45,000. Finally, Invesco Ltd. raised its position in Compass Therapeutics by 11.3% during the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company's stock valued at $57,000 after buying an additional 4,018 shares during the period. Institutional investors own 68.43% of the company's stock.

Insider Buying and Selling

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on CMPX. Jefferies Financial Group increased their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Monday. Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $4.00 to $6.00 in a report on Wednesday, April 2nd. Finally, Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Compass Therapeutics has a consensus rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Stock Up 3.8 %

Compass Therapeutics stock traded up $0.07 during mid-day trading on Friday, reaching $1.89. The company had a trading volume of 732,940 shares, compared to its average volume of 881,047. The firm has a market cap of $261.35 million, a price-to-earnings ratio of -5.11 and a beta of 1.40. The company has a 50 day moving average of $2.12 and a 200-day moving average of $2.10. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.